Zobrazeno 1 - 10
of 96
pro vyhledávání: '"Byron, Arana"'
Autor:
María Del Mar Castro, Astrid C Erber, Byron Arana, Gláucia Cota, Claudia M Denkinger, Nicole Harrison, Julia Kutyi, Liliana López-Carvajal, Emma Plugge, Julia Walochnik, Piero Olliaro
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 18, Iss 2, p e0011975 (2024)
BackgroundTarget Product Profiles (TPPs) are instrumental to help optimise the design and development of therapeutics, vaccines, and diagnostics - these products, in order to achieve the intended impact, should be aligned with users' preferences and
Externí odkaz:
https://doaj.org/article/46c673eaa69146a6b225bcd3c0ead175
Autor:
Maria Del Mar Castro, Joelle Rode, Paulo R L Machado, Alejandro Llanos-Cuentas, Marcia Hueb, Gláucia Cota, Isis Valentina Rojas, Yenifer Orobio, Oscar Oviedo Sarmiento, Ernesto Rojas, Juliana Quintero, Maria Inês Fernandes Pimentel, Jaime Soto, Carvel Suprien, Fiorela Alvarez, Ana Pilar Ramos, Rayssa Basílio Dos Santos Arantes, Rosiana Estéfane da Silva, Claudia Marcela Arenas, Ivan Darío Vélez, Marcelo Rosandiski Lyra, Nancy Gore Saravia, Byron Arana, Neal Alexander
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 17, Iss 1, p e0011029 (2023)
BackgroundTreatment guidance for children and older adult patients affected by cutaneous leishmaniasis (CL) is unclear due to limited representation of these groups in clinical trials.MethodsWe conducted a collaborative retrospective study to describ
Externí odkaz:
https://doaj.org/article/02a878a290dc45fb8bbfcef2c402dcf8
Autor:
Liliana López, Braulio Valencia, Fiorela Alvarez, Ana Pilar Ramos, Alejandro Llanos-Cuentas, Juan Echevarria, Iván Vélez, Marina Boni, Joelle Rode, Juliana Quintero, Alejandra Jiménez, Yulied Tabares, Claudia Méndez, Byron Arana
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 16, Iss 3, p e0010238 (2022)
BackgroundSystemic pentavalent antimonials, mainly meglumine antimoniate, continue to be the first-choice drugs for treatment of cutaneous leishmaniasis (CL) despite their toxicity, difficulty of administration and high cost. In the search for therap
Externí odkaz:
https://doaj.org/article/7d38ed91d4fd43ceaad0a96cea2a20d1
Autor:
Diana Caridha, Brian Vesely, Katrien van Bocxlaer, Byron Arana, Charles E. Mowbray, Sima Rafati, Silvia Uliana, Rosa Reguera, Mara Kreishman-Deitrick, Richard Sciotti, Pierre Buffet, Simon L. Croft
Publikováno v:
International Journal for Parasitology: Drugs and Drug Resistance, Vol 11, Iss , Pp 106-117 (2019)
Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and several novel compounds are currently in pre-clinical and clinical development for this manifestation of leishmaniasis, there have been limited advances
Externí odkaz:
https://doaj.org/article/e8feae56d3084dfcba7c0b0f20b1a9bd
Autor:
Seth G Thacker, Ian L McWilliams, Beatrice Bonnet, Lydia Halie, Serge Beaucage, Swaksha Rachuri, Ranadhir Dey, Robert Duncan, Farrokh Modabber, Stephen Robinson, Graeme Bilbe, Byron Arana, Daniela Verthelyi
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 14, Iss 2, p e0008050 (2020)
Cutaneous leishmaniasis (CL) affects the lives of 0.7-1 million people every year causing lesions that take months to heal. These lesions can result in disfiguring scars with psychological, social and economic consequences. Antimonials are the first
Externí odkaz:
https://doaj.org/article/d7284f9e62384f2481e13e85f6fb0f68
Autor:
Astrid C Erber, Byron Arana, Afif Ben Salah, Issam Bennis, Aicha Boukthir, María Del Mar Castro Noriega, Mamoudou Cissé, Gláucia Fernandes Cota, Farhad Handjani, Liliana López-Carvajal, Kevin Marsh, Dalila Martínez Medina, Emma Plugge, Trudie Lang, Piero Olliaro
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 14, Iss 2, p e0007996 (2020)
BackgroundCutaneous leishmaniasis (CL) is a disease that often affects exposed skin areas and may heal leaving lifelong scars. Patients' expectations from treatment are rarely considered in drug development for CL. An initiative aiming to address sho
Externí odkaz:
https://doaj.org/article/c36fe4e790ad4afe9fc49dadcbb4d093
Autor:
Israel Cruz, Audrey Albertini, Mady Barbeitas, Byron Arana, Albert Picado, Jose A. Ruiz-Postigo, Joseph M. Ndung'u
Publikováno v:
Parasite Epidemiology and Control, Vol 5, Iss , Pp - (2019)
Objectives: Localized cutaneous leishmaniasis and its evolving forms diffuse cutaneous leishmaniasis, mucosal leishmaniasis and cutaneous leishmaniasis recidivans, together with the visceral leishmaniasis sequelae post-kala azar dermal leishmaniasis
Externí odkaz:
https://doaj.org/article/863389dfa6cd4b0192e8529203dbae2c
Autor:
Yaimie Lopez, Byron Arana, Nidia Rizzo, Erick Duran, Álvaro Acosta-Serrano, Renata Mendizabal-Cabrera
Publikováno v:
Transactions of The Royal Society of Tropical Medicine and Hygiene.
Cutaneous leishmaniasis (CL) is a parasitic vector-borne disease affecting mostly low- and middle-income countries. CL is endemic in Guatemala, where an increase in the number of cases and incidence and a changing disease distribution in the past dec
Autor:
Maria del Mar Castro, Astrid Erber, Byron Arana, Glaucia Cota, Claudia Denkinger, Harrison Nicole, Kutyi Julia, Liliana López Carvajal, Emma Plugge, Julia Walochnik, Piero L. Olliaro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3ec58c260dcadb85ccbcfa1d0cfd4391
https://doi.org/10.2139/ssrn.4380035
https://doi.org/10.2139/ssrn.4380035
Autor:
Liliana López, Iván Vélez, Claudia Asela, Claudia Cruz, Fabiana Alves, Sara Robledo, Byron Arana
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 7, p e0006653 (2018)
BACKGROUND:Pentavalent antimonials (Sb5) are the first-line drugs for treating cutaneous leishmaniasis in Colombia; however, given problems with toxicity, compliance, availability, and cost, it is imperative to look for better therapeutic options. In
Externí odkaz:
https://doaj.org/article/40d5e15d0fb34f5cac91486e2d8db534